TrialCancer medicine2025

Phase 3 Study of Talazoparib Plus Enzalutamide Versus Placebo Plus Enzalutamide as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer: TALAPRO-2 Japanese Subgroup Analysis.

Nobuaki Matsubara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.